Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
venerdì, ottobre 23
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Treace Medical Concepts Inc
TMCI
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$4.30
0.02
0.47%
Ult. Agg.: Oct 22, 7:08 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 14 giorni da adesso in ven nov 6th, prima dell'apertura del mercato
Treace Medical Concepts Financials
Treace Medical Concepts (TMCI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.
Benzinga Newsdesk
PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $200.000M-$212.000M to $202.000M-$212.000M vs $205.920M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $200.000 million-$212.000 million to $202.000 million-$212.000 million vs $205.920 million estimate.
Benzinga Newsdesk
PRO
Treace Medical Concepts Q1 EPS $(0.28) Beats $(0.31) Estimate, Sales $47.198M Beat $45.960M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12 percent decrease over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Treace Medical Concepts Sees FY2026 Sales $200.000M-$212.000M vs $210.335M Est
2026 Financial OutlookThe Company is initiating full-year 2026 revenue guidance of $200 million to $212 million representing a decline of 6% to 0% compared to full-year 2025.The Company expects a loss in Adjusted EBITDA
Benzinga Newsdesk
Treace Medical Concepts Q4 Earnings Summary & Key Takeaways
Benzinga Insights
